Navigation Links
Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting

D1 Sunday, June 3, 2007 at 8:00 a.m. to 12:00 p.m. - Poster Discussion Presentation Session Title: Gynecologic Cancer Abstract No. 5516 "A Phase 2 trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer" Presenter: Nicoletta Colombo, M.D. Location: Display - E415a (Board 6), Discussion - E354a (11:00 am to 12:00 pm) Sunday, June 3, 2007 at 2:00 p.m. to 6:00 p.m. - Poster Presentation Session Title: Sarcoma Abstract No. 10076 "Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: Update of Phase 2 trial" Presenter: Sant P. Chawla, M.D. Location: Display - S Hall A2 (Board JJ4)

About AP23573

ARIAD's lead product candidate, AP23573, is a novel small-molecule inhibitor of the protein mTOR, a "master switch" in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. AP23573 is currently in Phase 1 and 2 clinical trials in patients with solid tumors and hematologic cancers. AP23573 has been designated both as a fast-track product and an orphan drug by the U.S. Food and Drug Administration and as an orphan drug by the European Medicines Agency for the treatment of soft-tissue and bone sarcomas. In addition to its program in oncology, ARIAD is collaborating with Medinol Ltd to develop stents and other medical devices that deliver AP23573 to prevent reblockage at sites of vascular injury following stent-assisted angioplasty.

About ARIAD

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. The Company is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. Medinol Ltd. also is developing stents and other medical devices that d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... declines and extinctions around the world have been ... but new research from the National Institute for ... pathogen, ranavirus, may also contribute. , In ... ranavirus, which causes severe hemorrhage of internal organs ... of wood frogs if they are exposed to ...
(Date:7/9/2014)... flatulence and have a reputation for being highly toxic, but ... now being being found to offer potential health benefits in ... and dementia. A new compound (AP39), designed and made at ... therapies, by targeting delivery of very small amounts of the ... , Scientists in Exeter have already found that the compound ...
(Date:7/9/2014)... the most important organs in the human body. Its ... properly this is its synthesis function and ... this is its detoxification function. Lack of exercise and ... the liver. The resulting diseased cells can lead to ... failure. According to the German Liver Foundation, over five ...
Breaking Medicine News(10 mins):Health News:Study cracks how the brain processes emotions 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... Sports as a,distributor of Muscle Pharm products throughout the US. ... and online,fulfillment. , "Having ... help service many,of our customers who call on a daily ... , For inquires about ...
... President of Preclinical Sciences and Marie Green, Ph.D., as ... CAMBRIDGE, Mass., Dec. 1 Taligen Therapeutics ... the appointment of Jeffrey T. Walsh as chief business ... Christopher Horvath, D.V.M., as vice president of preclinical sciences ...
... Computer Services,Inc. (NYSE: ACS ) re-enters the ... government agencies lower costs and increase service.,With the expiration ... a few,agencies, ACS can now offer its proven business ... As the U.S. faces ...
... generations often shared,wonderful memories of active and healthy grandparents ... years. In the last century, with,life expectancy having ... ages",are much more encumbered by health care concerns, which ... care for themselves. In the recently published,Evercare(R) Study of ...
... include information on the story of one soldier,s family who have ... wound of soldiers returning from Iraq is a traumatic brain injury, ... , ... Denver, CO (PRWEB) December 1, 2008 -- ...
... employers and recruiters to use just one source for all ... jobs posted by different employers across the country. Healthcare employers ... The Exchange simplifies and expedites the hiring process for the ... ...
Cached Medicine News:Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 2Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 3Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 2Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 3Health News:Take Time to Care for the Caregiver 2Health News:LegalView Updates Brain Injury Site with Information on TBI Disabled Soldier's Family 2Health News:LegalView Updates Brain Injury Site with Information on TBI Disabled Soldier's Family 3Health News:HeadHunterHealthExchange.com Launched to Enhance Healthcare Recruitment for Employers and Recruiters 2Health News:HeadHunterHealthExchange.com Launched to Enhance Healthcare Recruitment for Employers and Recruiters 3
Joseph skin hook is a single end-sharp with 2 prong....
Experience great vision, comfort and durability in a quarterly-replacement lens....
A unique lens system featuring Balanced Progressive Technology for optimum vision quality at every distance....
The proven daily wear spherical soft contact lens....
Medicine Products: